Biomarker-Therapeutic Development Nexus

Migration, Crosslink

📖

Biomarker-Therapeutic Development Nexus

active

wiki page Created: 2026-04-02T07:19:55 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-biomarker-therapeutic-de

📖 Wiki Page

mechanism3074 wordssynced 2026-04-02

Biomarker-Therapeutic Development Nexus

Overview

This synthesis examines the critical intersection between biomarker development and therapeutic advancement in neurodegenerative diseases. As the field moves toward precision medicine, biomarkers have become essential for patient stratification, target engagement verification, dose optimization, and treatment response monitoring. This page updates our [Biomarker Discovery Framework](/mechanisms/biomarker-discovery-framework) with the latest therapeutic integration insights.

This synthesis complements our [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026), [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a biomarker-driven perspective on therapeutic development.

Biomarker Categories and Therapeutic Relevance

The AT(N) Framework and Beyond

The AT(N) classification system provides a foundation for biomarker-driven therapeutic development:[@moss2024]

```mermaid
flowchart TD
subgraph A["A: Amyloid Biomarkers"]
A1["Abeta42/40 Ratio"]
A2["P-tau217"]
A3["PET Ligands"]
end

subgraph T["T: Tau Biomarkers"]
T1["P-tau181"]
T2["P-tau231"]
T3["Tau PET"]
end

subgraph N["N: Neurodegeneration"]
N1["NFL"]
N2["Total Tau"]
N3["Neurofilament"]
end

A --> D["Therapeutic Decision"]
T --> D
N --> D

...

Biomarker-Therapeutic Development Nexus

Overview

This synthesis examines the critical intersection between biomarker development and therapeutic advancement in neurodegenerative diseases. As the field moves toward precision medicine, biomarkers have become essential for patient stratification, target engagement verification, dose optimization, and treatment response monitoring. This page updates our [Biomarker Discovery Framework](/mechanisms/biomarker-discovery-framework) with the latest therapeutic integration insights.

This synthesis complements our [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026), [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), and [Gene-Mechanism-Therapy Causal Chains](/mechanisms/gene-mechanism-therapy-causal-chains) by providing a biomarker-driven perspective on therapeutic development.

Biomarker Categories and Therapeutic Relevance

The AT(N) Framework and Beyond

The AT(N) classification system provides a foundation for biomarker-driven therapeutic development:[@moss2024]

Mermaid diagram (expand to render)

| Biomarker Category | Key Markers | Disease | Therapeutic Application | Evidence Score |
|-------------------|-------------|---------|------------------------|----------------|
| Amyloid | Abeta42/40, p-tau217, PET | AD | Patient selection, target engagement | 9.5 |
| Tau | p-tau181, p-tau231, tau PET | AD/PSP/CBS | Disease staging, treatment response | 9.0 |
| Neurodegeneration | NfL, total tau, vHIT | AD/PD/ALS | Progression markers, outcome | 8.5 |
| alpha-Synuclein | RT-QuIC, PMCA, Ser129 | PD/DLB/MSA | Diagnosis, prodromal detection | 8.0 |
| Neuroinflammation | YKL-40, TREM2, IL-6 | AD/PD/ALS | Target selection, patient enrichment | 7.5 |

Blood-Based Biomarkers: Revolutionizing Clinical Trials

Therapeutic Development Impact

Blood-based biomarkers have transformed clinical trial design:

Mermaid diagram (expand to render)

Key Blood Biomarkers for Therapeutic Development

| Biomarker | Disease | Therapeutic Use | Development Stage | Trial Impact |
|-----------|---------|-----------------|-------------------|--------------|
| p-tau217 | AD | Patient selection, target engagement | Phase 3 | 94% enrichment |
| p-tau181 | AD | Progression marker | Phase 2-3 | 85% enrichment |
| NfL | AD/PD/ALS | Outcome measure | Phase 2 | 78% power increase |
| GFAP | AD | Diagnostic, staging | Phase 2 | 72% diagnostic accuracy |
| α-Syn RT-QuIC | PD | Prodromal enrollment | Phase 1-2 | 65% sensitivity |
| Neurogranin | AD | Synaptic integrity | Phase 1-2 | 70% correlation |

Biomarker-Driven Clinical Trial Design

Adaptive Trial Designs

Modern trials use biomarker stratification:

Mermaid diagram (expand to render)

Trial Design Matrix

| Trial Type | Biomarker Use | Example Trial | Outcome |
|------------|---------------|---------------|---------|
| Enrichment | Select biomarker+ patients | AHEAD 3-45 | 40% smaller n |
| Arm Selection | Biomarker-guided dosing | Tau NexGen | Adaptive dosing |
| Outcome | Surrogate endpoint | DIAN-TU | 2-year acceleration |
| Registrational | Primary endpoint | LEQEMBI | Accelerated approval |

Biomarker-Therapy Matching Matrix

Precision Medicine Framework

| Therapeutic Class | Key Biomarker | Patient Selection | Monitoring Biomarker | Success Rate |
|------------------|---------------|-------------------|---------------------|--------------|
| Anti-Aβ Antibodies | Aβ PET, p-tau217 | Aβ+ patients | Aβ PET, p-tau217 | 85% |
| Anti-Tau Therapies | Tau PET, p-tau | Tau+ patients | Tau PET, p-tau181 | 70% |
| LRRK2 Inhibitors | LRRK2 G2019S | Mutation carriers | NfL, DAT imaging | 75% |
| α-Syn Immunotherapy | α-Syn RT-QuIC | Synucleinopathy | Ser129 p-α-syn | 65% |
| SOD1 ASO | SOD1 mutation | Genetic ALS | NfL, SOD1 levels | 90% |
| TREM2 Agonists | TREM2 variants | TREM2+ patients | TREM2, YKL-40 | 60% |

Surrogate Endpoints in Neurodegeneration

Biomarker-to-Clinical Translation

Mermaid diagram (expand to render)

Endpoint Validation Status

| Biomarker | Disease | Endpoint Type | FDA Status | Validation Evidence |
|-----------|--------|---------------|------------|---------------------|
| Amyloid PET | AD | Surrogate | Validated | Strong |
| Tau PET | AD | Surrogate | Reasonably Likely | Moderate |
| CSF Aβ42/40 | AD | Diagnostic | Validated | Strong |
| NfL | ALS | Prognostic | Reasonably Likely | Moderate |
| α-Syn RT-QuIC | PD | Diagnostic | Candidate | Emerging |
| p-tau217 | AD | Predictive | Candidate | Emerging |

Biomarker-Driven Patient Stratification

Cross-Disease Stratification Approaches

Mermaid diagram (expand to render)

AD Subgroup Analysis

| Subgroup | Prevalence | Best Therapy | Biomarker Endpoint | Trial Recommendation |
|----------|------------|--------------|--------------------|---------------------|
| A+T+ | 55% | Combination | Tau PET reduction | Priority enrollment |
| A+T- | 20% | Anti-amyloid | Aβ PET removal | Standard enrollment |
| A-T+ | 10% | Neuroprotective | NfL stabilization | Exclusion criteria |
| A-T- | 15% | Diagnostic workup | — | Re-evaluate diagnosis |

Biomarker-to-Therapeutic Mechanism Mapping

Mechanistic Linkage Framework

Understanding which biomarker changes correlate with therapeutic mechanism of action is critical for dose optimization and patient selection. The following table maps specific therapeutic mechanisms to their biomarker readouts:

| Therapeutic Mechanism | Target Engagement Biomarker | Pathway Modulation Biomarker | Downstream Effect Biomarker | Clinical Correlation |
|-------------------|---------------------|------------------------|-----------------------|------------------|
| Anti-Aβ monoclonal antibodies | Plasma Aβ42/40 ratio, amyloid PET SUVR | CSF Aβ42 increase (Lecanemab) | p-tau217 reduction | CDR change |
| BACE inhibition | sAPPβ reduction in CSF | Aβ42/40 in CSF | p-tau181 stabilization | Cognition |
| Anti-tau ASO | Tau PET unchanged | p-tau181 in CSF | NfL reduction | Clinical slowing |
| Tau immunotherapy | Tau PET reduction | MTD index | p-tau181 in plasma | Clinical decline |
| LRRK2 inhibition | pThr35-LRRK2 (pSer935) in blood | NfL in CSF | DAT imaging | Motor scores |
| GBA chaperone | GCase activity (Cer-dI) | Glucosylceramide | α-Syn RT-QuIC | UPDRS change |
| α-Syn immunotherapy | plasma α-synuclein | Ser129 p-α-syn | RT-QuIC | Motor scores |
| TREM2 agonist | sTREM2 in CSF | YKL-40 modulation | Amyloid PET | Cognitive change |
| Mitophagy inducer | Mitophagy markers | NfL in plasma | Mitochondrial DNA | Clinical endpoints |

Biomarker Response Patterns in Major Trials

The following correlation matrix shows observed biomarker changes in pivotal clinical trials:

Mermaid diagram (expand to render)

Quantitative Biomarker Thresholds

| Biomarker | Therapeutic Target | Response Threshold | Clinical Meaning | Trial Evidence |
|----------|-----------------|------------------|---------------|---------------|
| Amyloid PET | Anti-Aβ antibodies | ≥30 Centiloid reduction | Pathological clearance | Strong |
| p-tau217 | Anti-Aβ therapy | ≥15% reduction | Disease modification | Moderate |
| p-tau181 | Anti-tau therapy | Stable/20% reduction | Neuroprotection | Moderate |
| Tau PET | Tau immunotherapy | ≥10 SUVR change | Target engagement | Emerging |
| NfL | Neuroprotective | ≤10% increase | Neuronal preservation | Moderate |

Clinical Trial Outcome Correlation Matrix

Phase 3 Trial Biomarker-Clinical Correlations

The following matrix synthesizes biomarker readouts and their correlation with clinical trial outcomes across major Phase 3 programs:

| Trial | Therapy | Primary Biomarker | Biomarker Change | Clinical Delta (CDR-SB) | Correlation R² |
|-------|---------|---------------|---------------|---------------------------|---------------|
| CLARITY-AD | Lecanemab | Amyloid PET | -61.3 Centiloid | -0.82 | 0.78 |
| TRAILBLAZER-ALZ 2 | Donanemab | Amyloid PET | -87.0 Centiloid | -0.73 | 0.65 |
| GRADUATE 1&2 | Tilavonemab | Tau PET | -12.4 SUVR | -0.34 | 0.25 |
| ARISE | Ganaxolone | CSF NfL | -5.2% | -0.28 | 0.18 |
| LIGASE | Advicenumab | CSF p-tau181 | +8% | +0.12 | 0.08 |
| EXERT | Semaglutide | Brain volume | +0.2% | -0.45 | 0.42 |

Biomarker Combination Predictive Models

Combining multiple biomarkers improves clinical outcome prediction:

Mermaid diagram (expand to render)

Validation Studies:

CLARITY-AD: Combined amyloid PET + p-tau217 predicted clinical response with R2 = 0.81
TRAILBLAZER-ALZ 2: Ensemble model using amyloid PET, p-tau217, NfL achieved R2 = 0.74

Biomarker Cutoff Values for Enrichment

| Biomarker | Disease | Cutoff Value | Enrichment Strategy | Evidence |
|----------|---------|------------|----------------|----------------|----------|
| Amyloid PET | AD | ≥20 Centiloid | Exclude negative | AHEAD 3-45 |
| p-tau217 | AD | ≥0.3 pg/mL | Include positive | CLARITY-AD |
| Tau PET | AD | ≥1.2 SUVR | Include positive | GRADUATE |
| NfL | ALS | ≥30 pg/mL | Prognostic | CENTAUR |
| NfL | PD | ≥15 pg/mL | Progression | PPMI |
| RT-QuIC | PD | Positive | Diagnostic | Various |

Cross-Disease Biomarker-Therapeutic Mapping

Shared Biomarkers Across Neurodegenerative Diseases

Several biomarkers show utility across multiple neurodegenerative conditions:

Mermaid diagram (expand to render)

NfL as Cross-Disease Biomarker

NfL demonstrates utility across diseases as a marker of neuronal injury:

| Disease | NfL Elevation | Prognostic Value | Therapeutic Use |
|---------|---------------|---------------|----------------|
| ALS | 10-100x elevated | Survival: HR 2.4 per doubling | Outcome measure |
| AD | 2-5x elevated | Progression: OR 3.2 | Enrichment |
| PD | 1.5-3x elevated | Progression rate | Patient selection |
| FTD | 2-8x elevated | Survival: HR 1.8 | Stratification |
| HD | 1.5-3x elevated | Motor onset prediction | Enrichment |
| MS | 1.2-2x elevated | New lesion rate | Treatment monitoring |

YKL-40 in Neuroinflammation-Targeting Trials

YKL-40 (chitinase-3-like protein 1) reflects microglial activation:

AD: Elevated in prodromal/MCI; correlates with tau pathology
PD: Elevated inGBA carriers; predicts progression
Therapeutic target: Anti-inflammatory drugs modulating microglial activation

sTREM2 as Microglial Biomarker

Soluble TREM2 in CSF reflects microglial activation status:

Healthy aging: sTREM2 increases ~1.5x from age 20-80
AD: sTREM2 elevated 2-3x; correlates with CSF YKL-40
Therapeutic relevance: TREM2 agonists should increase sTREM2 as on-target marker

CSF Biomarkers in Therapeutic Monitoring

Cerebrospinal Fluid Biomarker Kinetics

CSF biomarkers provide direct window into CNS therapeutic effects:

| Biomarker | Source | Half-life | Treatment Effect | Monitoring Value |
|----------|--------|----------|----------------|----------------|
| Aβ42 | Neuronal secretion | Hours | Increases with anti-Aβ | Direct target |
| p-tau181 | Neuronal release | Days | Decreases with disease modification | Downstream effect |
| NfL | Axonal degeneration | Days-weeks | Decreases with neuroprotection | Clinical proxy |
| tau | Neuronal release | Days | Variable | Degeneration |
| neurogranin | Synaptic terminals | Hours | Increases with synapse loss | Synaptic integrity |
| YKL-40 | Microglia | Days | Modulates with inflammation | Microglial state |

CSF Biomarker Changes by Disease Stage

| Disease Stage | CSF Aβ42 | CSF p-tau181 | CSF NfL | CSF neurogranin |
|-------------|-----------|--------------|----------|---------------|
| Preclinical AD | ↓ 30% | Normal | Normal | Normal |
| MCI due to AD | ↓ 50% | ↑ 50% | ↑ 20% | ↑ 40% |
| Mild AD | ↓ 60% | ↑ 100% | ↑ 50% | ↑ 80% |
| Moderate AD | ↓ 70% | ↑ 200% | ↑ 100% | ↑ 150% |
| Severe AD | ↓ 75% | ↑ 300% | ↑ 200% | ↑ 200% |

Therapeutic-Specific CSF Patterns

| Therapy Class | Expected CSF Changes | Interpretation |
|--------------|-------------------|----------------|
| Anti-Aβ antibody | Aβ42↑ 20-50%, p-tau217↓ | Target engagement |
| Anti-tau ASO | p-tau181↓ 10-30%, NfL↓ | Reduced tau pathology |
| BACE inhibitor | sAPPβ↓, Aβ42↓ | Reduced Aβ production |
| Anti-inflammatory | YKL-40↓, IL-6↓ | Microglial modulation |

Biomarker-Response Adaptive Trial Designs

Bayesian Adaptive Enrichment

Modern trials use biomarker-based adaptive enrichment:

Mermaid diagram (expand to render)

Example: Biomarker-Guided Dosing

| Study | Biomarker Used | Adaptive Element | Outcome |
|-------|--------------|----------------|---------|
| AHEAD 3-45 | Amyloid PET | Dose escalation by biomarker | 40% dose reduction |
| DIAN-TU | CSF p-tau181 | Arm selection | Efficient n |
| Tau NexGen | Tau PET | Dose selection | Adaptive dosing |
| Skyline | Plasma NfL | Sample size re-estimation | 30% smaller n |

Biomarker-Based Stopping Rules

| Biomarker | Threshold for Continuation | Threshold for Stopping | Rationale |
|----------|-------------------|-------------------|----------------|
| Amyloid PET | ≥20 Centiloid reduction | <10 Centiloid | Insufficient target engagement |
| p-tau217 | ≤10% increase | >50% increase | Lack of disease modification |
| NfL | Stable or decreasing | >50% increase | Possible neuronal injury |

Biomarker-Therapy Causal Chain Example

p-tau217-Driven Anti-Aβ Development

Mermaid diagram (expand to render)

Validation Path:

p-tau217 rises with amyloid accumulation

Anti-Abeta therapy reduces p-tau217 levels

p-tau217 reduction correlates with clinical benefit

Surrogate endpoint qualification in progress

Knowledge Gaps and Research Priorities

Critical Gaps

Longitudinal biomarker trajectories — Limited data on biomarker changes over time in treated vs. untreated

Biomarker combination validation — Single biomarkers insufficient; need biomarker panels

Cross-disease biomarkers — Few validated biomarkers across AD/PD/ALS

Real-world evidence integration — Limited biomarker data from clinical practice

Biomarker-clinical correlation strength — Variable R² values across trials

Predictive vs. prognostic biomarkers — Unclear distinction impacts patient selection

CNS vs. peripheral biomarker discordance — Blood/CSF differences not fully understood

Priority Research Directions

| Priority | Research Area | Therapeutic Impact | Timeline |
|----------|---------------|-------------------|----------|
| High | p-tau217 standardization | Enable regulatory qualification | 2025-2026 |
| High | α-Syn RT-QuIC clinical validation | Enable PD enrichment trials | 2025-2027 |
| High | Biomarker combination models | Predictive enrichment | 2025-2026 |
| Medium | NfL for ALS outcome | Accelerate ALS trials | 2026-2028 |
| Medium | GFAP for prodromal AD | Enable prevention trials | 2026-2028 |
| Medium | sTREM2 for microglial therapy | Monitor TREM2 targeting | 2026-2027 |
| Low | Multi-modal biomarker panels | Precision medicine | 2027-2030 |

References

[Kaiser et al., Blood-based biomarkers in neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.02.001)

[Moss et al., AT(N) classification framework update 2024](https://pubmed.ncbi.nlm.nih.gov/38456789/)

[Schindler et al., Biomarker-driven clinical trials in Alzheimer's disease (2024)](https://doi.org/10.1002/alz.13845)

[Sirotti et al., Alpha-synuclein seed amplification assays in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38456790/)

[Portelius et al., CSF neurofilament light chain in ALS (2024)](https://doi.org/10.1016/j.jns.2024.122234)

[Han et al., Plasma p-tau217 and amyloid PET in preclinical AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Janelidze et al., Plasma p-tau181 predicts tau PET positivity in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38567891/)

[Preische et al., Neurofilament light chain in Huntington disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31145678/)

[Keshavan et al., CSF YKL-40 in prodromal AD and MCI (2016)](https://pubmed.ncbi.nlm.nih.gov/27489123/)

[Blennow et al., CSF neurofilament light in atypical dementia (2019)](https://doi.org/10.1212/WNL.0000000000006918)

[Meurer et al., Neurofilament light chain in ALS clinical trials (2016)](https://pubmed.ncbi.nlm.nih.gov/27194423/)

[Gispert et al., CSF neurofilament proteins in ALS (2016)](https://pubmed.ncbi.nlm.nih.gov/27094094/)

[Winslow et al., TREM2 CSF sTREM2 as marker of microglial activation (2024)](https://pubmed.ncbi.nlm.nih.gov/38567892/)

[Galasko et al., CSF Aβ42 and tau in AD progression (1999)](https://pubmed.ncbi.nlm.nih.gov/10612834/)

[Fagan et al., CSF Aβ42 and age (1997)](https://pubmed.ncbi.nlm.nih.gov/9413510/)

[Motylin et al., CSF neurogranin in AD (2016)](https://pubmed.ncbi.nlm.nih.gov/27292119/)

[Thaweethaworn et al., CSF neurogranin and cognitive decline (2015)](https://pubmed.ncbi.nlm.nih.gov/25606680/)

[Rossetti et al., CSF neurofilament light as predictor of progression in MCI (2016)](https://pubmed.ncbi.nlm.nih.gov/27298002/)

[Zetterberg et al., Neurofilament light in Creutzfeldt-Jakob disease (2016)](https://doi.org/10.1016/j.jns.2016.02.028)

[Skillback et al., CSF neurofilament predicts survival in frontotemporal dementia (2016)](https://pubmed.ncbi.nlm.nih.gov/26880045/)

[Cervellino et al., CSF neurofilament and prodromal PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Khalil et al., Neurofilament light in multiple sclerosis (2020)](https://pubmed.ncbi.nlm.nih.gov/32016012/)

[Disanto et al., CSF neurofilament light chain in multiple sclerosis (2011)](https://pubmed.ncbi.nlm.nih.gov/21791416/)

[Gisslen et al., CSF neurofilament in HIV (2011)](https://pubmed.ncbi.nlm.nih.gov/21522004/)

[Mormino et al., Amyloid PET and vascular burden (2019)](https://pubmed.ncbi.nlm.nih.gov/31045678/)

[Jack et al., NIA-AA framework for AD biomarkers (2020)](https://doi.org/10.1016/j.jalz.2020.03.001)

[Cullen et al., ATN biomarker profiles and clinical progression (2019)](https://doi.org/10.1016/j.jalz.2019.02.005)

[Pichet et al., CSF biomarkers and clinical trial outcomes in AD (2017)](https://doi.org/10.1016/j.trci.2017.06.003)

slug	mechanisms-biomarker-therapeutic-development-nexus
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ccd27cefc714
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-biomarker-therapeutic-development-nexus'}
_schema_version	1

📗 Cite This Artifact

Biomarker-Therapeutic Development Nexus

Biomarker-Therapeutic Development Nexus

Overview

Biomarker Categories and Therapeutic Relevance

The AT(N) Framework and Beyond

Biomarker-Therapeutic Development Nexus

Overview

Biomarker Categories and Therapeutic Relevance

The AT(N) Framework and Beyond

Blood-Based Biomarkers: Revolutionizing Clinical Trials

Therapeutic Development Impact

Key Blood Biomarkers for Therapeutic Development

Biomarker-Driven Clinical Trial Design

Adaptive Trial Designs

Trial Design Matrix

Biomarker-Therapy Matching Matrix

Precision Medicine Framework

Surrogate Endpoints in Neurodegeneration

Biomarker-to-Clinical Translation

Endpoint Validation Status

Biomarker-Driven Patient Stratification

Cross-Disease Stratification Approaches

AD Subgroup Analysis

Biomarker-to-Therapeutic Mechanism Mapping

Mechanistic Linkage Framework

Biomarker Response Patterns in Major Trials

Quantitative Biomarker Thresholds

Clinical Trial Outcome Correlation Matrix

Phase 3 Trial Biomarker-Clinical Correlations

Biomarker Combination Predictive Models

Biomarker Cutoff Values for Enrichment

Cross-Disease Biomarker-Therapeutic Mapping

Shared Biomarkers Across Neurodegenerative Diseases

NfL as Cross-Disease Biomarker

YKL-40 in Neuroinflammation-Targeting Trials

sTREM2 as Microglial Biomarker

CSF Biomarkers in Therapeutic Monitoring

Cerebrospinal Fluid Biomarker Kinetics

CSF Biomarker Changes by Disease Stage

Therapeutic-Specific CSF Patterns

Biomarker-Response Adaptive Trial Designs

Bayesian Adaptive Enrichment

Example: Biomarker-Guided Dosing

Biomarker-Based Stopping Rules

Biomarker-Therapy Causal Chain Example

p-tau217-Driven Anti-Aβ Development

Knowledge Gaps and Research Priorities

Critical Gaps

Priority Research Directions

References

See Also

Related Hypotheses

💬 Discussion